OTC: IPSEF - Ipsen S.A.

Rentabilidade por seis meses: +2.5%
Rendimento de dividendos: +0.96%
Setor: Healthcare

Cronograma de promoção Ipsen S.A.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Ipsen S.A.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma.

mais detalhes
The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета eur
Див.доход ао 0.9639
Дивиденд ао 1.16
Сайт https://www.ipsen.com
Цена ао 120.55
Alteração de preço por dia: 0% (120.55)
Alteração de preço por semana: 0% (120.55)
Alteração de preço por mês: 0% (120.55)
Alteração de preço em 3 meses: -3.84% (125.37)
Mudança de preço em seis meses: +2.5% (117.61)
Mudança de preço por ano: +2.51% (117.6)
Mudança de preço desde o início do ano: -3.84% (125.37)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 2.63 6
P/BV 2.15 7
P/E 12.77 8
EV/EBITDA 8.63 8
Total: 7.88

Eficiência

Nome Significado Nota
ROA, % 10.19 4
ROE, % 16.85 5
Total: 5

Dividendos

Nome Significado Nota
Div yield, % 0.9639 2.4
DSI 0.8571 8.57
Total: 3.06

Obrigação

Nome Significado Nota
Debt/EBITDA 0.4137 10
Total: 9.8

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 22.79 4
Rentabilidade Ebitda, % 4.08 1
Rentabilidade EPS, % -1246.72 0
Total: 2.8
Mais detalhes



Supervisor Cargo Pagamento Ano de nascimento
Mr. David Loew MD, CEO & Director 2.41M 1967 (58 anos)
Mr. Aymeric Le Chatelier Executive VP & CFO 792.51k 1969 (56 anos)
Dr. Aidan Murphy Ph.D. Executive VP and Head of Technical Operations N/A 1966 (59 anos)
Mr. Craig Marks Vice-President of Investor Relations N/A
Mr. Francois Garnier Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer N/A 1962 (63 ano)
Mr. Regis Mulot Executive VP & Chief Human Resources Officer N/A 1966 (59 anos)
Ms. Dominique Bery Head of Nordics & Baltics N/A 1971 (54 ano)
Mr. Bartosz Bednarz D.D.S. Executive VP and Head of Global Product & Portfolio Strategy N/A
Mr. Philippe Lopes-Fernandes CBO Executive VP & Chief Business Officer N/A
Dr. James Levine M.D., Ph.D. President of Fondation Ipsen

Endereço: France, Boulogne-Billancourt, 65 quai Georges Gorse - abrir no Google Maps, abrir mapas Yandex
Site: https://www.ipsen.com